Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12577MR)

This product GTTS-WQ12577MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ12577MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11438MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ1091MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ2384MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ1666MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ1479MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ9221MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-106
GTTS-WQ9422MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ6637MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DI-17E6
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW